Contrast

Contact

Share

MyChart

Help

Northeast Medical Group expansion tackles rare genetic disorder known as Gaucher disease hero

Wednesday, August 4, 2021

New Rochelle, NY (Aug. 4, 2021) – In an effort to widen patient access to the treatment of a rare genetic disorder, Yale School of Medicine’s National Gaucher Disease Treatment Center has expanded to include a third location in New Rochelle, NY.

The New York location makes it easier for patients to access care, including people who travel from all parts of the United States and the world to see Pramod Mistry, MD, PhD, the center’s director and a professor of Medicine and Pediatrics at Yale School of Medicine. Other locations include New Haven and Stamford, CT.

“A major danger of Gaucher disease is lack of awareness. People wait an average of five years before receiving an accurate diagnosis. Additionally, not many providers have experience treating the disease,” said Dr. Mistry, an expert in the field for three decades.

Located at 145 Huguenot St. in New Rochelle, the Gaucher program is integrated with the Northeast Medical Group Obstetrics and Gynecology office, creating opportunities for genetic testing which can mitigate potential risks for the baby if both parents carry the mutation. Physicians at the center also can provide ongoing care to women who have Gaucher (since the disease can progress during pregnancy) and to women who discover for the first time that they have Gaucher disease during pregnancy.

What is Gaucher disease?

Worldwide, Gaucher disease affects 1 in 40,000 people, but its frequency is as high as 1 in 450 births among people of Ashkenazic (Eastern European) Jewish decent. There are approximately 6,000 people with Gaucher disease in the United States.

Individuals with Gaucher disease have macrophages – the cells responsible for eliminating damaged cells – that lack the enzyme to break down a molecule called glucocerebroside. As a result, the molecule overwhelms the macrophage, turning it into what is called a Gaucher cell, which then accumulate in bone marrow, the liver and the spleen. Once there, they cause inflammation and scar tissue responsible for many symptoms of Gaucher disease, such as bone pain, organ enlargement, osteoporosis, bone infarction, anemia, fatigue, excessive bleeding and bruising. Some patients also are at risk of cancers and Parkinson disease.

Gaucher disease is not yet curable, but most types are treatable with regular infusions of a synthetic enzyme. While the disease is present at birth, symptoms can appear at any age. Early diagnosis and treatment are vital to the best outcomes. Diagnosis involves a genetic test and a blood test that measures enzyme activity. Dr. Mistry is studying a new treatment for Gaucher disease that could minimize the need for infusions.

Eliminating stigmas

In addition to providing medical care, Dr. Mistry wants to lessen the stigma associated with genetic disorders such as Gaucher disease. “I learned quite late in my career about the trauma the whole family experiences shuttling to different doctors and thinking they passed on the wrong genes. Every human on this planet is a carrier of several dozen genetic diseases,” he said. “I would like to remove the label of genetic disease when I discuss this condition – the psychological burden shouldn’t be any more than high cholesterol. This is a very complex condition, and our core mission is to deliver science-driven holistic care.”

Northeast Medical Group (NEMG) is a not-for-profit multispecialty medical foundation established in 2010. NEMG integrates physicians across Yale New Haven Health and helps provide more coordinated, comprehensive, safe and high quality health care for patients across the entire continuum – primary, specialty, inpatient, outpatient, rehabilitative and preventive care. NEMG represents more than 120 locations and 835 physicians and medical professionals affiliated with Bridgeport, Greenwich, Lawrence + Memorial, Westerly and Yale New Haven hospitals. www.northeastmedicalgroup.org

Similar Articles

10/21/2021

Eric P. Winer to lead Yale Cancer Center and Smilow Cancer Hospital

After an extensive national search, Yale School of Medicine and Yale New Haven Health have announced that Eric P. Winer, M.D., will be the next director of Yale Cancer Center (YCC) and physician-in-chief of Smilow Cancer Hospital at Yale New Haven, effective February 1, 2022.

10/13/2021

Lawrence + Memorial Hospital using precision medicine to treat breast cancer

NEW LONDON, CT (Oct. 13, 2021) Yale New Haven Health is bringing precision medicine to breast cancer patients at Lawrence + Memorial Hospital (L+M) with a new imaging agent that is designed specifically to detect certain types of recurrent or metastatic breast cancer.

10/13/2021

Northeast Medical Group announces improved quality, excellent patient experience and higher shared savings

Stratford, CT (Oct. 13, 2021) – Northeast Medical Group (NEMG), part of Yale New Haven Health, has announced that successful efforts to enhance quality of care, better coordinate care and deliver superior patient experience have led to over $13 million in shared savings from the Centers for Medicare and Medicaid Services (CMS) in the past year.

Media Contact

Magaly Olivero
Tel. 203-863-3463
Email